PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First-Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study.

• Tác giả: Xin An, Yuchen Cai, Meiting Chen, Rishang Chen, Tinghua Gao, Anqi Hu, Riqing Huang, Yunjie Huang, Haifeng Li, Shuo Li, Yanxia Shi, Ditian Shu, Cong Xue, Qiufan Zheng, Zhousan Zheng
• Ngôn ngữ: eng
• Ký hiệu phân loại: 025.3173 Bibliographic analysis and control
• Thông tin xuất bản: China : MedComm , 2025
• Bộ sưu tập: NCBI
• ID: 219954

Tóm tắt

 This multicenter study aimed to investigate the efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy (ICI-Chemo group) versus chemotherapy alone (Chemo group) for patients with cancer of unknown primary (CUP) in the first-line setting. We included patients with unfavorable CUP across four medical centers in China. Between January 2014 and December 2023, 117 patients were enrolled: 46 patients in the ICI-Chemo group and 71 patients in the Chemo group. After a median follow-up of 28.1 months, the ICI-Chemo group exhibited a significant improvement over the Chemo group in median PFS (9.10 months vs. 6.37 months
  hazard ratio [HR] 0.46
  95% CI: 0.30-0.71